## **Listing of Claims:**

Claim 1 (currently amended): A compound of Formula I below:

wherein:

W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate; [[,]]

W<sup>1</sup> and W<sup>2</sup> are independently selected from the group consisting of hydrogen and a pharmaceutically acceptable prodrug;

R is selected from the group consisting of hydrogen or  $(C_1-C_3)$  alkyl;

R<sup>1</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

Y is a bond,  $-CH_2$ - or -O-;

Y' is selected from the group consisting of hydrogen, halo, hydroxyl, thioalkyl, amino and substituted amino;

Z is selected from the group consisting of <u>formyl</u>, <u>aeyl</u>, <u>eyano</u>, <u>earboxyl</u>, <u>earboxyl</u> ester,  $-C(O)NR^{20}R^{21}$ , halo,  $-B(OH)_2$ ,  $-C(=NR^2)R^3$ , nitro, alkenyl, substituted alkenyl, acetylenyl and substituted acetylenyl of the formula  $-C=C-R^4$ ;

where  $R^2$  is selected from the group consisting of hydrogen, -OH, -OR<sup>5</sup> amino, substituted amino, and  $(C_1-C_2)$ alkyl, where  $R^5$  is selected from the group consisting of alkyl and substituted alkyl;

R<sup>3</sup> is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino and substituted amino;

SVCA\_20155.1

R<sup>4</sup> is selected from the group consisting of hydrogen, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, -Si(R<sup>8</sup>)<sub>3</sub>, carboxyl, carboxyl esters, and -C(O)NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> are independently hydrogen, alkyl or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen atom pendent thereto are joined to form a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group; and

each R<sup>8</sup> is independently (C<sub>1</sub>-C<sub>4</sub>)alkyl or phenyl; and

R<sup>20</sup>-and R<sup>21</sup>-are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or R<sup>20</sup>-and R<sup>21</sup>, together with the nitrogen atom pendent thereto form a heterocyclic or substituted heterocyclic group;

or pharmaceutically acceptable salts thereof.

Claim 2 (currently amended): A compound of claim 1 wherein, W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate.

Claims 3-4 (canceled).

Claim 5 (currently amended): A compound of Formula II

II

wherein:

W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate and a pharmaceutically acceptable prodrug;

SVCA\_20155.1

R is selected from the group consisting of hydrogen or  $(C_1-C_3)$  alkyl;

Z is selected from the group consisting of <u>formyl</u>, <u>aeyl</u>, <u>eyano</u>, <u>earboxyl</u>, <u>earboxyl</u> <u>ester</u>,  $-C(O)NR^{20}R^{21}$ , halo,  $-B(OH)_2$ ,  $-C(=NR^2)R^3$ , nitro, alkenyl, substituted alkenyl, acetylenyl and substituted acetylenyl of the formula  $-C=C-R^4$ ;

where R<sup>2</sup> is selected from the group consisting of hydrogen, -OH, -OR<sup>5</sup> amino, substituted amino, and (C<sub>1</sub>-C<sub>2</sub>)alkyl, where R<sup>5</sup> is selected from the group consisting of alkyl and substituted alkyl;

R<sup>3</sup>-is selected from the group consisting of hydrogen, alkyl, substituted alkyl, amino and substituted amino;

R<sup>4</sup> is selected from the group consisting of hydrogen, phenyl, substituted phenyl, heteroaryl, substituted heteroaryl, -Si(R<sup>8</sup>)<sub>3</sub>, carboxyl, carboxyl esters, and -C(O)NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> are independently hydrogen, alkyl or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen atom pendent thereto are joined to form a heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl group; and

each R<sup>8</sup> is independently (C<sub>1</sub>-C<sub>4</sub>)alkyl or phenyl; and

R<sup>20</sup>-and R<sup>21</sup>-are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic or R<sup>20</sup>-and R<sup>21</sup>, together with the nitrogen atom pendent thereto form a heterocyclic or substituted heterocyclic group;

or pharmaceutically acceptable salts thereof.

Claim 6 (currently amended): A compound of claim 5 wherein, W is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate.

Claim 7 (canceled).

Claim 8 (currently amended): A compound of Claim 7 1 or 5 wherein, Z is selected from formyl, nitro, bromro bromo, iodo, and  $-C \equiv C-R^4$  and  $R^4$  is selected from H, phenyl, and  $-Si(CH_3)_3$ .

- Claim 9 (currently amended): A compound selected from the group consisting of:
  - 1-(6-hydroxylamino-7-ethynyl-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (1);
- 1-(6-hydroxylamino-7-(2-phenylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (2);
- 1-(6-hydroxylamino-7-(2-(pyridin-2-yl)-ethyn-1-yl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (3);
- 1-(6-hydroxylamino-7-(2-(4-fluorophenyl)ethyn-1-yl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (4);
- 1-(6-hydroxylamino-7-(2-(4-methylphenyl)ethyn-1-yl)-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (5);
- 1-(6-hydroxylamino-7-(2-carboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (6);
- 1-(6-hydroxylamino-7-(2-ethyl carboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose (7);
- <u>1-(6-hydroxylamino-7-(2-ethylcarboxylethyn-1-yl)-7-deazapurin-9-yl)-2-methyl-</u> β-D-ribofuranose (7);
- 1-(6-hydroxylamino-7-(2-carboxamidoethyn-1-yl)-7-deazapurin-9-yl)-2-methyl- $\beta$ -D-ribofuranose (8);
- $\label{eq:continuous} 1\mbox{-}(6\mbox{-hydroxylamino-}7\mbox{-}(2\mbox{-trimethylsilylethyn-}1\mbox{-yl})\mbox{-}7\mbox{-deazapurin-}9\mbox{-yl})\mbox{-}2\mbox{-methyl-}\beta\mbox{-} \\ D\mbox{-ribofuranose}\ (9);$
- 1-(6-hydroxylamino-7-ethenyl-7-deaza- purin-9-yl)-2-methyl-β-D-ribofuranose (10);

```
1-(6-hydroxylamino-7-formyl-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose
(11);
       1-(6-hydroxylamino-7-(carbaldehyde oxime))-7-deazapurin-9-yl)-2-
methyl-β-D-ribofuranose (12);
       1-(6-hydroxylamino-7-(boronic acid)-7-deazapurin-9-yl)-2-methyl-β-D-
ribofuranose (13);
       1-(6-hydroxylamino-7-(boronic acid)-7-deazapurin-9-yl)-2-methyl-β-D-
ribofuranose (13);
       1-(6-hydroxylamino-7-(2,2-difluorovinyl)-7-deazapurin-9-yl)-2-methyl-β-D-
ribofuranose (14);
       1-(6-hydroxylamino-7-(2-cis-methoxyvinyl)-7-deazapurin-9-yl)-2-methy-β-D-
ribofuranose (15);
       1-(6-hydroxylamino-7-nitro-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (16);
       1-(6-hydroxylamino 7-cyano 7-deaza- purin-9-yl)-2-methyl-β-D-ribofuranose
(17);
       1-(6-methoxyamino-7-ethynyl-7-deazapurin-9-yl)-2-methyl-β-D-ribofuranose
(18);
       1-(6-methoxyamino-7-nitro-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose (19);
       1-(6-methoxyamino-7-formyl-7-deaza-purin-9-yl)-2-methyl-β-D-ribofuranose
(20);
       and pharmaceutically acceptable salts thereof.
```

Claim 10 (original): A pharmaceutical compositions comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of any one of Claims 1, 5 and 9.

Claims 11-12 (canceled).